FindTrial
Sign In

Dexamethasone (Oral)

DRUG2 trials

Sponsors

Bristol-Myers Squibb, The Netherlands Cancer Institute

Conditions

Breast CancerLymphomaMultiple Myeloma

Phase 2

DiEtary Mimicry by Glucocorticoid Modulation Evaluation in ER+ Metastatic Breast Cancer Treatment: Efficacy and Response (DEMETER Trial)
Not yet recruitingNCT07786051
The Netherlands Cancer InstituteBreast Cancer
Start: 2026-11-01End: 2028-11-01Target: 80Updated: 2026-08-25

Phase 3

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
CompletedNCT01239797
Bristol-Myers SquibbLymphoma, Multiple Myeloma
Start: 2011-06-20End: 2021-04-21Updated: 2022-06-01

Related Papers

Using electronic health records to derive a synthetic control arm for a historical trial on relapsed/refractory multiple myeloma.
Journal of Clinical Oncology2022-06-01
Population pharmacokinetic and exposure-response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma.
2021-11-263 citations
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study.
2020-09-0496 citations
Quality-of-Life Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Treated with Elotuzumab Plus Lenalidomide/Dexamethasone or Lenalidomide/Dexamethasone: Final Analysis of the Phase 3 ELOQUENT-2 Study
Blood2019-11-131 citations
INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma
Future Oncology2019-02-2829 citations
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4‐year follow‐up and analysis of relative progression‐free survival from the randomized ELOQUENT‐2 trial
Cancer2018-09-11139 citations
Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study
Annals of Hematology2018-09-0318 citations
Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab + lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).
Journal of Clinical Oncology2018-05-2011 citations
Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling.
2018-02-1513 citations
Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Vs Ld in Patients with Newly Diagnosed Multiple Myeloma: Phase 2, Randomized, Open-Label Study in Japan
Blood2017-12-074 citations
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: <scp>ELOQUENT</scp>‐2 follow‐up and <i>post‐hoc</i> analyses on progression‐free survival and tumour growth
British Journal of Haematology2017-07-05131 citations
Phase 3 ELOQUENT-2 study: Extended four year follow-up (FU) of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).
Journal of Clinical Oncology2017-05-209 citations
An Integrated Assessment of the Effects of Immunogenicity on the Pharmacokinetics, Safety, and Efficacy of Elotuzumab.
2017-01-098 citations
Safety and Efficacy of Elotuzumab with Lenalidomide/Dexamethasone for Multiple Myeloma in a Japanese Subpopulation Analysis of the Phase 3 Eloquent-2 Trial
Blood2016-12-02
The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective.
2016-09-2714 citations
ELOQUENT-2 update: Phase III study of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM)—Identifying responders by subset analysis.
Journal of Clinical Oncology2016-05-208 citations
Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up
Blood2015-12-0328 citations
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
New England Journal of Medicine2015-06-021301 citations
ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Journal of Clinical Oncology2015-05-2022 citations